AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01265888
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM
Trial: NCT01265888
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
Trial: NCT00003637
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03599752
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive chemotherapy
Trial: NCT02270983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02351973
Drug: Hydrochlorthiazide
RxNorm normalized name: HYDROCHLORTHIAZIDE 25MG/VALSARTAN 160MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Trial: NCT02670343
Drug: Oral Testosterone Undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
Trial: NCT02351973
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Trial: NCT02351973
Drug: Hydrochlorthiazide and Amiloride
RxNorm normalized name: amiloride / hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 12.5 to 25mg \& + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Trial: NCT00361257
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline antibiotic, 100 mg taken orally every 12 hours
Trial: NCT00361257
Drug: Placebo (Tetracycline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline antibiotic placebo, orally every 12 hours
Trial: NCT01797419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral liquid, .5 mL/kg
Trial: NCT03739853
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Used in all three arms of study
Trial: NCT01147458
Drug: PF-04191834 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching PF-04191834 placebo tablets to be administered BID for two weeks
Trial: NCT02199860
Drug: SD I
RxNorm normalized name: Alphanine SD Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02199860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01147458
Drug: Naproxen placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching naproxen placebo tablets to be administered BID for 4 weeks
Trial: NCT01585233
Drug: ASKP1240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT04082832
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension
Trial: NCT01147458
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg tablet administered BID for a total of four weeks
Trial: NCT02856997
Drug: Chidamide with ICE regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chidamide and ICE regimen, dosage described in arm description
Trial: NCT04440345
Drug: IBI362
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT04440345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT04194905
Drug: Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated Tablets
Trial: NCT04194905
Drug: Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated Tablets
Trial: NCT01483690
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally to all patients the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35
Trial: NCT00090051
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT06346236
Drug: L-thyroxine at a dose of 7.5 µg/kg/d for THOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects diagnosed with THOP (as previously defined) and treated with L-thyroxine at a dose of 7.5 µg/kg/d are less likely to have an impaired ASQ score at 4 years of corrected age.
Trial: NCT03449108
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02781519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
Trial: NCT01389518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
Trial: NCT04338984
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.
Trial: NCT01074021
Drug: placebo plus chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)
Trial: NCT01041495
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo for cyclobenzaprine ER (AMRIX)
Trial: NCT01572675
Drug: etorocoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as 30 mg or 60 mg oral film-coated tablets
Trial: NCT01572675
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as 100 mg or 200 mg oral hard capsules
Trial: NCT00236925
Drug: Low dose Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 10 mg daily
Trial: NCT00236925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04118296
Drug: Anti-Acne Preparations for Topical Use
RxNorm normalized name: ANTI-ACNE PREPARATIONS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
Trial: NCT00038883
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day x 5, starting with the first day of chemotherapy
Trial: NCT00214630
Drug: rosuvastatin calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00377975
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01691755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral doses once a day for 26 weeks
Trial: NCT00145600
Drug: 2 alternating cycles of VAMP/COP chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
Trial: NCT00145600
Drug: 3 alternating cycles of VAMP/COP chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
Trial: NCT02669238
Drug: Minidril®/Leeloo®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
Trial: NCT03137030
Drug: Norco 5Mg-325Mg Tablet
RxNorm normalized name: Norco 5mg-325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
Trial: NCT00162721
Drug: doxorubicin, ifosfamide, cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03174041
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose rosuvastatin
Trial: NCT03174041
Drug: Rosuvastatin and GDC-0853
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Multiple doses GDC-0853 and single dose rosuvastatin
Trial: NCT03174041
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose simvastatin
Trial: NCT03174041
Drug: Simvastatin and GDC-0853
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses GDC-0853 and single dose simvastatin
Trial: NCT01553032
Drug: Erbitux®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
Trial: NCT02030054
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
Trial: NCT01266941
Drug: Inhaled FF 200mcg/GW642444M 25mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
Trial: NCT01052844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
Trial: NCT04565184
Drug: Artemether, Lumefantrine Drug Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
Trial: NCT03924856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
Trial: NCT00368329
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO bid daily on RT days: 500mg \& 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
Trial: NCT02171702
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02160353
Drug: Abiraterone acetate, Prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01670604
Drug: 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01670604
Drug: Tetraspan, B. Braun, Melsungen, Germany
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00368329
Drug: [18-F] Fluorodeoxyglucose (FDG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-10 mCi IV administration
Trial: NCT00272961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet once daily for 12 weeks
Trial: NCT00272961
Drug: TBC3711
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tablets once daily for 10 weeks
Trial: NCT00272961
Drug: TBC3711
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tablet once daily for 10 weeks
Trial: NCT00272961
Drug: TBC3711
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet once daily for 10 weeks
Trial: NCT01292785
Drug: Hormones
RxNorm normalized name: Other hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FtM will receive~* 1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~* if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~* 50mg cyproterone acetate daily (Androcur®)~* estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is \> 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is \< 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~* 2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss.
Trial: NCT03039751
Drug: AdvVEGF-D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdvVEGF-D will be injected into 10 sites of the myocardium
Trial: NCT00272961
Drug: TBC3711
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tablet once daily for 10 weeks
Trial: NCT00961766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose IV matched placebo
Trial: NCT00559936
Drug: Topical Avastin 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avastin (bevacizumab) 1%
Trial: NCT02145988
Drug: DLBS1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
Trial: NCT02145988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
Trial: NCT04115644
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
Trial: NCT02212431
Drug: Cysteamine
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
Trial: NCT02009007
Drug: dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous infusion during operation
Trial: NCT00956956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally Q6 hours for 7 days of dosing.
Trial: NCT00969904
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet TID for 12 weeks
Trial: NCT03647332
Drug: Steroid Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroid injection
Trial: NCT02794740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External Spray
Trial: NCT00330798
Drug: nepafenac 0.1%
RxNorm normalized name: NEPAFENAC 0.1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
Trial: NCT01397864
Drug: rhC1INH or pdC1INH
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
Trial: NCT02675231
Drug: Standard of Care Single Agent Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
Trial: NCT02238977
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant
Trial: NCT00676585
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT00676585
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 100mg
Trial: NCT01504867
Drug: Lactose powder
RxNorm normalized name: Lactose Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching lactose powder filled capsules will be administered on days 1-7.
Trial: NCT00571922
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT02827513
Drug: CTN XR1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03888924
Drug: Bacille Calmette-Guerin vaccine
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride.
Trial: NCT03888924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isotonic solution of sodium chloride (2mL vials).
Trial: NCT05438641
Drug: BZDP-Based Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.
Trial: NCT00371488
Drug: GW572016 oral tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
Trial: NCT00160966
Drug: Ciclosporin and Mycophenolate-mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: according to the Giessen protocol
Trial: NCT00160966
Drug: Tacrolimus and Mycophenolate-mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: according to Giessen protocol
Trial: NCT04714099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01254045
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal placebo (48 international units)